MacroGenics to Participate in Upcoming Investor Conference
17 mai 2022 16h01 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, May 17, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the...
MacroGenics to Participate in Upcoming Investor Conferences
03 mars 2022 16h01 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, March 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
MacroGenics Announces Executive Promotion
28 févr. 2022 07h00 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 28, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
Triumph Bancorp to Present at the Raymond James 43rd Institutional Investors Conference on March 7, in Orlando, Florida
24 févr. 2022 16h07 HE
|
Triumph Bancorp, Inc.
DALLAS, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Triumph Bancorp, Inc. (Nasdaq: TBK) today announced that Aaron Graft, Vice Chairman and CEO, will present at the Raymond James 43rd Institutional Investors...
MacroGenics to Participate in Upcoming Investor Conferences
03 févr. 2022 16h01 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
Standard to Present at the Bank of America Securities Virtual Battery and Storage Conference
06 janv. 2022 16h29 HE
|
Standard Lithium
VANCOUVER, British Columbia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE: SLI) (FRA: S5L), an innovative technology and lithium...
MacroGenics to Participate in Upcoming Investor Conferences
03 nov. 2021 16h01 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Nov. 03, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021
16 sept. 2021 02h45 HE
|
MacroGenics, Inc.
21 of 40 patients (53%) achieved confirmed responses by independent review, exceeding prespecified futility boundary for trial; enrollment proceeding to Part 2 of Cohort A78% of patients had tumor...
MacroGenics Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presented at ESMO 2021 Virtual Annual Congress
16 sept. 2021 02h45 HE
|
MacroGenics, Inc.
Metastatic castration-resistant prostate cancer (mCRPC): 21 of 39 patients (54%) achieved ≥ 50% prostate-specific antigen (PSA) reduction; 10 of 16 (63%) RECIST-evaluable patients had anti-tumor...
MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress
12 sept. 2021 19h00 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Sept. 12, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...